Nitrooxymethyl-Substituted Analogues of Rofecoxib: Synthesis and Pharmacological Characterization
作者:Donatella Boschi、Clara Cena、Antonella Di Stilo、Barbara Rolando、Paola Manzini、Roberta Fruttero、Alberto Gasco
DOI:10.1002/cbdv.200900421
日期:2010.5
properties, are closely dependent on the position at which the NO‐donor nitrooxymethyl function is introduced into the Rofecoxib scaffold. All the products were capable of dilating rat aorta strips precontracted with phenylephrine in a dose‐dependent manner, through a cGMP‐dependent mechanism. Compound 10 emerged as a quite potent COX‐2‐selective inhibitor endowed with good vasodilator activity. Interestingly
合成了罗非昔布的硝基氧甲基取代衍生物,并测试了它们在全人血中的环氧合酶 (COX) 抑制活性、对大鼠主动脉条的血管扩张效力,以及它们抑制人富含血小板的血浆血小板聚集的能力。结果表明,它们在抑制 COX 异构体方面的效力和选择性,以及它们的抗聚集特性,密切依赖于将 NO 供体硝基氧甲基功能引入罗非昔布支架的位置。所有产品都能够通过 cGMP 依赖性机制以剂量依赖性方式扩张与去氧肾上腺素预收缩的大鼠主动脉条。化合物 10 是一种非常有效的 COX-2 选择性抑制剂,具有良好的血管扩张活性。有趣的是,化合物 19 是一种有效的选择性 COX-1 抑制剂,并显示出良好的血管扩张剂和抗凝集特性。羟甲基衍生物,硝基氧甲基类似物的潜在代谢物,也进行了类似的比较研究。